Plasma and urinary excretion kinetics of oral baclofen in healthy subjects

Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly exc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of clinical pharmacology 1989-03, Vol.37 (2), p.181-184
Hauptverfasser: WUIS, E. W, DIRKS, M. J. M, TERMOND, E. E. S, VREE, T. B, VAN DER KLEIJN, E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 184
container_issue 2
container_start_page 181
container_title European journal of clinical pharmacology
container_volume 37
creator WUIS, E. W
DIRKS, M. J. M
TERMOND, E. E. S
VREE, T. B
VAN DER KLEIJN, E
description Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.
doi_str_mv 10.1007/bf00558228
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79228875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79228875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</originalsourceid><addsrcrecordid>eNo9kM1Lw0AUxBdRaq1evAt7EA9C9O0mm90ctVg_KOhBz2E_3tLUNNHdBOx_b6Sxpze8-TEwQ8g5gxsGIG-NBxBCca4OyJRlKU8YZOyQTAFSluSFhGNyEuMagIkC0gmZcFlwJtMpeXmrddxoqhtH-1A1Omwp_tiAXdU29LNqBmEjbT1tg66p0bZuPTa0augKdd2ttjT2Zo22i6fkyOs64tl4Z-Rj8fA-f0qWr4_P87tlYlMpu8RZJ5jMjUBp8kJnRrCsMEoJh5mxkKs848prgV5Zb2ThALhHjsPLOUCWzsjVLvcrtN89xq7cVNFiXesG2z6WQzWulBQDeL0DbWhjDOjLr1BthoYlg_JvuPJ-8T_cAF-Mqb3ZoNuj41KDfzn6Olpd-6AbW8U9lktZiEylv4yNdZY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79228875</pqid></control><display><type>article</type><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</creator><creatorcontrib>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</creatorcontrib><description>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/bf00558228</identifier><identifier>PMID: 2792173</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Baclofen - blood ; Baclofen - pharmacokinetics ; Baclofen - urine ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; Female ; Humans ; Hydrogen-Ion Concentration ; Male ; Medical sciences ; Muscle ; Pharmacology. Drug treatments ; Reference Values ; Spectrometry, Fluorescence ; Spectrophotometry, Ultraviolet</subject><ispartof>European journal of clinical pharmacology, 1989-03, Vol.37 (2), p.181-184</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</citedby><cites>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=6779548$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2792173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WUIS, E. W</creatorcontrib><creatorcontrib>DIRKS, M. J. M</creatorcontrib><creatorcontrib>TERMOND, E. E. S</creatorcontrib><creatorcontrib>VREE, T. B</creatorcontrib><creatorcontrib>VAN DER KLEIJN, E</creatorcontrib><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</description><subject>Adult</subject><subject>Baclofen - blood</subject><subject>Baclofen - pharmacokinetics</subject><subject>Baclofen - urine</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle</subject><subject>Pharmacology. Drug treatments</subject><subject>Reference Values</subject><subject>Spectrometry, Fluorescence</subject><subject>Spectrophotometry, Ultraviolet</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1Lw0AUxBdRaq1evAt7EA9C9O0mm90ctVg_KOhBz2E_3tLUNNHdBOx_b6Sxpze8-TEwQ8g5gxsGIG-NBxBCca4OyJRlKU8YZOyQTAFSluSFhGNyEuMagIkC0gmZcFlwJtMpeXmrddxoqhtH-1A1Omwp_tiAXdU29LNqBmEjbT1tg66p0bZuPTa0augKdd2ttjT2Zo22i6fkyOs64tl4Z-Rj8fA-f0qWr4_P87tlYlMpu8RZJ5jMjUBp8kJnRrCsMEoJh5mxkKs848prgV5Zb2ThALhHjsPLOUCWzsjVLvcrtN89xq7cVNFiXesG2z6WQzWulBQDeL0DbWhjDOjLr1BthoYlg_JvuPJ-8T_cAF-Mqb3ZoNuj41KDfzn6Olpd-6AbW8U9lktZiEylv4yNdZY</recordid><startdate>198903</startdate><enddate>198903</enddate><creator>WUIS, E. W</creator><creator>DIRKS, M. J. M</creator><creator>TERMOND, E. E. S</creator><creator>VREE, T. B</creator><creator>VAN DER KLEIJN, E</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198903</creationdate><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><author>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Baclofen - blood</topic><topic>Baclofen - pharmacokinetics</topic><topic>Baclofen - urine</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle</topic><topic>Pharmacology. Drug treatments</topic><topic>Reference Values</topic><topic>Spectrometry, Fluorescence</topic><topic>Spectrophotometry, Ultraviolet</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WUIS, E. W</creatorcontrib><creatorcontrib>DIRKS, M. J. M</creatorcontrib><creatorcontrib>TERMOND, E. E. S</creatorcontrib><creatorcontrib>VREE, T. B</creatorcontrib><creatorcontrib>VAN DER KLEIJN, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WUIS, E. W</au><au>DIRKS, M. J. M</au><au>TERMOND, E. E. S</au><au>VREE, T. B</au><au>VAN DER KLEIJN, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1989-03</date><risdate>1989</risdate><volume>37</volume><issue>2</issue><spage>181</spage><epage>184</epage><pages>181-184</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>2792173</pmid><doi>10.1007/bf00558228</doi><tpages>4</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0031-6970
ispartof European journal of clinical pharmacology, 1989-03, Vol.37 (2), p.181-184
issn 0031-6970
1432-1041
language eng
recordid cdi_proquest_miscellaneous_79228875
source MEDLINE; SpringerLink Journals
subjects Adult
Baclofen - blood
Baclofen - pharmacokinetics
Baclofen - urine
Biological and medical sciences
Chromatography, High Pressure Liquid
Female
Humans
Hydrogen-Ion Concentration
Male
Medical sciences
Muscle
Pharmacology. Drug treatments
Reference Values
Spectrometry, Fluorescence
Spectrophotometry, Ultraviolet
title Plasma and urinary excretion kinetics of oral baclofen in healthy subjects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20and%20urinary%20excretion%20kinetics%20of%20oral%20baclofen%20in%20healthy%20subjects&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=WUIS,%20E.%20W&rft.date=1989-03&rft.volume=37&rft.issue=2&rft.spage=181&rft.epage=184&rft.pages=181-184&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/bf00558228&rft_dat=%3Cproquest_cross%3E79228875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79228875&rft_id=info:pmid/2792173&rfr_iscdi=true